Filana Therapeutics receives Nasdaq notice on minimum bid shortfall
Nasdaq notified Filana Therapeutics that its common stock failed the $1.00 minimum bid price for 30 consecutive business days under Listing Rule 5550(a)(2). The company has until March 16, 2027 to regain compliance by achieving a $1…